Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals Incorporated
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Reshma Kewalramani
- Employees
- 6,400
- Market cap
- $126.7 B
- IPO
- 24/07/1991
- Web
- www.vrtx.com
Vertex Pharmaceuticals Incorporated is a leading biotechnology company focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers several approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA for…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Vertex Pharmaceuticals stock: price history
1D
-1.8%
1W
-2.0%
1M
-2.6%
6M
+13.3%
YTD
+10.2%
1Y
+22.3%
2Y
+2.6%
5Y
+174.9%
10Y
+502.4%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~15% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Vertex Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Vertex Pharmaceuticals is a leading biotechnology company specializing in the discovery and commercialization of innovative treatments, with a clear focus on cystic fibrosis (CF) therapy. The company markets established medications such as Trikafta, Symdeko/Symkevi, Orkambi, and Kalydeco, with a very high proportion of revenue generated through these CF therapies. The clinical pipeline encompasses research activities in various areas, including sickle cell disease, type 1 diabetes, and various pain therapeutics. Distribution occurs through specialized pharmacies, wholesalers, retail chains, and clinics across both the US and international markets.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Ask the agents about Vertex Pharmaceuticals
Analyst assessment of Vertex Pharmaceuticals
PRICE TARGET LOW
US$350.00
CONSENSUS
US$573.50
MEDIAN
US$601.50
PRICE TARGET HIGH
US$665.00
0
STRONG BUY
47
BUY
8
HOLD
1
SELL
0
STRONG SELL
56
TOTAL · Buy
As of: 08/10/2026
Vertex Pharmaceuticals stock metrics
P/E
28.85
P/B
6.27
EV/EBITDA
22.26
RETURN ON EQUITY
5.4%
NET MARGIN
33.0%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
252,881,588
AVG. DAILY VOLUME (30D)
1,119,363
Insider transactions (SEC)
van Grunsven Jasper
Ambrose Kristen
SACHS BRUCE I
Sachdev Amit
Tatsis Ourania
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.8%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Vertex Pharmaceuticals stock
What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals Incorporated is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Reshma Kewalramani, the company employs around 6,400 people.
The IPO was on 24/07/1991; the stock trades on NASDAQ under the ticker VRTX.
What do analysts say about Vertex Pharmaceuticals stock?
56 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$573.50, ranging from US$350.00 to US$665.00, with a median of US$601.50.
This is an external assessment, not a statement by Market Jury.
When does Vertex Pharmaceuticals report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 15% stronger than usual.
Does Vertex Pharmaceuticals pay a dividend?
No, Vertex Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Vertex Pharmaceuticals?
Comparable stocks include Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences, Summit Therapeutics and Halozyme Therapeutics.
How can I get Vertex Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vertex Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.